Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diabetes Drug May Reverse Alzheimer's and Enters Major Clinical Trial

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
A commonly prescribed diabetes drug could reverse memory loss and the build-up of plaques on the brain linked to Alzheimer's.

The research is published in Neuropharmacology. The findings come as the charity prepares the next phase of its Drug Discovery programme which aims to repurpose existing drugs as dementia treatments in as little as five to ten years.

Results from the study, led by Professor Christian Hölscher at Lancaster University, show that liraglutide might be able to reverse some of the damage caused by Alzheimer's disease in the later stages of the condition. Mice with late-stage Alzheimer's given the drug performed significantly better on an object recognition test and their brains showed a 30 per cent reduction in the build-up of toxic plaques.

Liraglutide is a member of a class of drugs known as a GLP-1 analogue. The drug is used to stimulate insulin production in diabetes, but research shows it can also pass through the blood brain barrier and have a protective effect on brain cells.

Alzheimer's Society's flagship Drug Discovery programme seeks to repurpose existing drugs for use in dementia. An earlier study of liraglutide funded by the charity showed promising results in mice with early stage Alzheimer's. This research now demonstrates the drug's potential as a treatment in the later stages of the condition. A major clinical trial led by Dr Paul Edison of Imperial College London and partly funded by Alzheimer's Society to test the effectiveness of the drug in people with Alzheimer's disease will also begin recruiting patients in the next few weeks.

Alzheimer's disease is the most common form of dementia. The condition is caused by diseases of the brain and is characterised by the slow death of brain cells. It is progressive, there are few effective treatments and as yet there is no cure. If successful in clinical trials liraglutide will be the first new dementia treatment in a decade.

Dr Doug Brown, Director of Research and Development at Alzheimer's Society said:

'Developing new drugs from scratch can take 20 years and hundreds of millions of pounds. We owe it to the 800,000 people with dementia in the UK to do everything we can to accelerate the process. Our focus on repurposing existing drugs as dementia treatments is an incredibly exciting way of bringing new treatments closer.

This exciting study suggests that one of these drugs can reverse the biological causes of Alzheimer's even in the late stages and demonstrates we're on the right track. We're now funding a major new trial to bring it closer to a position where it can be improving the lives of people with dementia.'


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!